1. Home
  2. PLG vs CRBU Comparison

PLG vs CRBU Comparison

Compare PLG & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Platinum Group Metals Ltd. (Canada)

PLG

Platinum Group Metals Ltd. (Canada)

HOLD

Current Price

$2.79

Market Cap

250.1M

Sector

N/A

ML Signal

HOLD

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

HOLD

Current Price

$1.61

Market Cap

203.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLG
CRBU
Founded
2000
2011
Country
Canada
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
250.1M
203.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PLG
CRBU
Price
$2.79
$1.61
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
4.5M
1.0M
Earning Date
01-13-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$9,295,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.62
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$0.66
52 Week High
$3.36
$3.54

Technical Indicators

Market Signals
Indicator
PLG
CRBU
Relative Strength Index (RSI) 59.34 40.12
Support Level $2.44 $1.52
Resistance Level $2.66 $1.80
Average True Range (ATR) 0.18 0.09
MACD -0.00 0.01
Stochastic Oscillator 85.93 25.00

Price Performance

Historical Comparison
PLG
CRBU

About PLG Platinum Group Metals Ltd. (Canada)

Platinum Group Metals Ltd is the operator of the Waterberg Project, a bulk underground PGM deposit located in South Africa. Waterberg was discovered by Platinum Group and is being jointly developed with Implats, the Japan Oil, Gas and Metals National Corporation (JOGMEC) and Hanwa Co. Ltd. Waterberg has the potential to be a large-scale, low-cost producer of palladium, platinum, rhodium, and gold. Geographically, it operates in Canada and South Africa.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Share on Social Networks: